Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
especially Products
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
 

Mifebort Taj Products

 
HOME >> PRODUCTS >> Taj Products >> Mifebort
Taj  ALL Products View Products According to Category


Each film coated tablet contains

Composition

Mifepristone.....................................................................200 mg
Excipients........ ....................................................................q.s.

Indications
Mifebort is indicated for the medical termination of intrauterine pregnancy through 49 days pregnancy. For purposes of this treatment, pregnancy is dated from the first day of the last menstrual period in a presumed 28 day cycle with ovulation occurring at mid-cycle. Any intrauterine device [IUD] should be removed before treatment with Mifebort begins. Patients taking Mifebort must take 400 mg of Misobort two days after taking mifepristone unless a complete abortion has already been confirmed before that time (see Dosage And Administration). Pregnancy termination by surgery is recommended in cases when Mifebort and Misobort fail to cause termination of intrauterine pregnancy.

Description
Mifepristone blocks the hormone progesterone needed to maintain the pregnancy. Because this hormone is blocked, the uterine lining begins to shed, the cervix begins to soften and bleeding may occur. With the later addition of the second medication, misoprostol, the uterus contracts and the pregnancy is usually expelled within 6 to 8 hours.
Because the woman decides when to take the second medication within the time frame of 24 to 72 hours after the first medication, she has some control over when she experiences the miscarriage and its side effects. Some women choose the Abortion Pill because of the privacy it offers. Some women feel empowered by taking an active role in the process.
Mifepristone effect on reproductive system

Side Effects
Most of the side effects when using this early abortion option are caused by the second medication, misoprostol. Side-effects may include heavy bleeding, headache, nausea, vomiting, diarrhea, and heavy cramping.

Dosage
Treatment with Mifebort and Misobort for the termination of pregnancy requires three office visits by the patient. Mifebort may be administered only in a clinic, medical office, or hospital, by or under the supervision of a gynecologist, able to assess the gestational age of an embryo and to diagnose ectopic pregnancies. Gynecologist must also be able to provide surgical intervention in cases of incomplete abortion or severe bleeding, if necessary. Mifebort. Unless abortion has occurred and has been confirmed by clinical examination or ultrasonographic scan, the patient takes two 200 mg tablets (400 mg) of Misobort orally.

Presentations
1 tablet

Mifebort-Mifepristone Mifebort-Taj-Pharma


Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited)

Mifebort ® Logo



Mifebort



 


Mifebort2







 

 

 

 

 

 

              
 Print page   Send by mail


 

   
   
PRODUCTS
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM
 

   

 

 

 

 

 

 

 

 
 www.tajpharma.com

   

 

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement